Cogent Biosciences, Inc. (COGT) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 10 Buy, 2 Hold.
The consensus price target is $48.13 (low: $35.00, high: $60.00), representing an upside of 31.9% from the current price $36.49.
Analysts estimate Earnings Per Share (EPS) of $-2.42 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.49 vs est $-2.42 (missed -44.3%). 2025: actual $-2.55 vs est $-2.27 (missed -12.5%). Analyst accuracy: 79%.
COGT Stock — 12-Month Price Forecast
$48.13
▲ +31.90% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Cogent Biosciences, Inc., the average price target is $48.13, with a high forecast of $60.00, and a low forecast of $35.00.
The average price target represents a +31.90% change from the last price of $36.49.
Highest Price Target
$60.00
Average Price Target
$48.13
Lowest Price Target
$35.00
COGT Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Cogent Biosciences, Inc. in the past 3 months
EPS Estimates — COGT
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$3.49
vs Est –$2.42
▼ 30.7% off
2025
Actual –$2.55
vs Est –$2.27
▼ 11.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — COGT
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
